# A Phase 2A Trial of DT402 for Autism Spectrum Disorder

> **NCT07303907** · PHASE2 · RECRUITING · sponsor: **Definium Therapeutics US, Inc.** · enrollment: 20 (estimated)

## Conditions studied

- Autism Spectrum Disorder
- ASD

## Interventions

- **DRUG:** DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))

## Key facts

- **NCT ID:** NCT07303907
- **Lead sponsor:** Definium Therapeutics US, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-03
- **Primary completion:** 2027-08
- **Final completion:** 2027-08
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07303907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07303907, "A Phase 2A Trial of DT402 for Autism Spectrum Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07303907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*